Lilly(Eli) & Co (LLY) Company Profile & Statistics

Lilly(Eli) & Co
LLY
(NYSE)
N/A
803.33
+20.15 (+2.57%)
in:usd•As of: May 21, 2024 15:59 UTC -4
After Market:804.4+1.07 (+0.13%)
Open
792.44
High
816.11
Low
791.00

About Lilly(Eli) & Co

CEO

David Ricks

Headquarters

lilly corporate center

indianapolis, in 46285, united states

Auditor

Ernst & Young LLP

Employees

43,000

Share Holders

18,871

Website

www.lilly.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.

Lilly(Eli) & Co Statistics

Valuation Measures

Market Capitalization ²	763.49B
Enterprise Value	787.24B
Enterprise Value/EBITDA (ttm)	87.10
Price to Earnings Ratio (ttm)	105.77
Price to Book (mrq)	56.74
Price to Sales (ttm)	20.37
Price to Cash (ytd)	100.96

Profitability

Gross Margin (ttm)	80.12%
Operating Margin (ttm)	18.32%
Profit Margin (ttm)	17.40%
Return on Equity (ttm)	56.98%
Return on Invested Capital (ttm)	19.31%
Return on Assets (ttm)	10.94%

Income Statement

Revenue (ttm)	35.93B
Revenue Per Share (ttm)	37.81
Gross Profit (ttm)	28.80B
EBITDA (ttm)³	9.04B
Net Income Avi to Common (ttm)	6.14B
Diluted EPS (ttm)	6.79

Share Statistics

Beta (5Y Monthly)	0.37
52-Week Change	86.49%
S&P500 52-Week Change	26.92%
S&P500 Member	Yes
Stock Optionable	Yes
Total Shares Outstanding ¹	950.41M
Dividend Yield	0.68%
Float ⁴	949.17M
% Held by Insiders	0.13%
% Held by Institutions	82.53%

Balance Sheet

Total Cash (mrq)	2.59B
Total Cash Per Share (mrq)	2.72
Total Debt (mrq)	26.21B
Total Debt/Equity (mrq)	203.23%
Current Ratio (mrq)	1.35%
Quick Ratio (mrq)	1.03%
Book Value Per Share (mrq)	13.57

Cash Flow

Operating Cash Flow Per Share (ytd)	1.29
Free Cash Flow (ytd)	179.70M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Lilly(Eli) & Co

Trade With A Regulated Broker